Why the Nordics and Baltics need their own market entry plan
Medical device companies expanding in Europe usually start with Germany, France or the United Kingdom, and often leave the Nordic and Baltic countries for later. That is understandable, since the populations are small. But companies that already sell well in larger markets are often surprised when the same approach produces little in Helsinki, Stockholm or Tallinn. The reason is not the size of the market but the way it buys.
Most purchasing goes through public tenders
Healthcare in the Nordic countries is largely publicly funded and publicly provided, and hospitals buy most of their devices through competitive tenders. The buyers are regional rather than national in most cases: the wellbeing services counties in Finland, the regions in Sweden and Denmark, and the regional health authorities in Norway, which also use a joint procurement organisation. A single tender can cover every hospital in a region for several years. Winning it can establish a product; missing it can close a region until the next round.
Relationships still matter, but differently
Tender rules limit what sales representatives can do once a procurement has started, and award criteria are published. Influence comes earlier, through clinical evidence, product evaluations at the hospital and clinicians' input into the technical specification. A company that first engages with a hospital when the tender is announced is usually too late.
The Baltics are not a single market
Estonia, Latvia and Lithuania are often grouped together, and many distributors cover all three. Their health systems, payers and procurement practices differ, however, and so does the speed of adoption. A plan that treats them as one territory may suit a distributor's organisation but not the way each country buys.
What this means for a market entry plan
For the Nordic and Baltic countries I would build the plan around the tender calendar rather than a sales territory. That means identifying which regions and hospital groups buy the relevant product category, when their current contracts expire, and what the last award criteria were. It also means choosing a distributor whose strength is winning and administering tenders, and starting clinical evaluations well before the next procurement round opens.
The markets are small, but they are stable, they pay on time and their clinicians are often early adopters of well-evidenced technology. For many companies they are worth the effort of a separate plan.
I am based in Finland and work in these markets directly. If you are considering the Nordic or Baltic countries, you can reach me through the contact form on this site.
